ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...

Abby Markward, MBA, executive director of the ASCRS Foundation and ASOA, discusses the foundation's global initiatives and the ASCRS Party for a Purpose.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

New ISO standards categorize SVIOLs into multifocal, EDOF, and FVR IOLs, requiring rigorous clinical testing for ...

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts ...

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and ...

Biocon Biologics and Regeneron Pharmaceuticals settled to commercialize aflibercept-jbvf in the US, resolving patent ...

Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...